Cargando…
2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer
BACKGROUND: Selected patients with peritoneal metastases of colorectal cancer (PM-CRC) can benefit from potentially curative cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC), with a median overall survival (OS) of more than 40 months. OBJECTIVE: The aims of this eviden...
Autores principales: | Hübner, Martin, van Der Speeten, Kurt, Govaerts, Kim, de Hingh, Ignace, Villeneuve, Laurent, Kusamura, Shigeki, Glehen, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695877/ https://www.ncbi.nlm.nih.gov/pubmed/37940803 http://dx.doi.org/10.1245/s10434-023-14368-5 |
Ejemplares similares
-
Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
por: Graf, Wilhelm, et al.
Publicado: (2019) -
Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial
por: Bakkers, C., et al.
Publicado: (2023) -
In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
por: Said, Ibrahim, et al.
Publicado: (2022) -
Treatment Strategies and Prognosis of Patients With Synchronous or Metachronous Colorectal Peritoneal Metastases: A Population-Based Study
por: Bakkers, C., et al.
Publicado: (2021) -
Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?
por: Khan, Sohini, et al.
Publicado: (2022)